I could start on that, Madam Chair.
As we looked at the candidates from a vaccine point of view, there are some vaccine platforms that have been used in programs since the 1950s when we started to roll out public health programs, so we would have a lot more experience and knowledge about their technical ability to be ramped up and their safety in big populations, for example, pertussis vaccine or influenza vaccine.
During this pandemic we had some very novel platforms, particularly the mRNAs.What we did was look across the entire science of how you evaluate a vaccine: its immune response; the pre-clinical studies, that is the studies in animals; any toxicology studies; any evidence in humans; and then all those technical aspects of biomanufacturing that Mark has mentioned, to come to a decision and looking at it from all the aspects that we mentioned.